INTRODUCTION
Infused monoclonal antibodies enjoy significant success as cancer immunotherapies, but it has proved harder to exploit the equivalent promise of infused T lymphocytes. [1] [2] [3] Many tumor-associated target antigens are functionally weak stimulators of the immune response. 4 Consequently, preparation of tumor antigen-specific T cells for infusion requires specialized APC. Since these APC are required during both the induction and the amplification phase of the anti-tumor T cell response, large numbers of APC are necessary. This is problematic in many cancer patients whose APC may be numerically and functionally defective, due to the disease or its treatment. 5 Even when tumor-specific cytotoxic (CD8 + ) T cells are successfully prepared 6 , lack of T helper (CD4 + ) cell function in vivo may lead to lack of in vivo expansion, a problem that is not overcome by infusion of large numbers of cells. [6] [7] [8] Finally, although successful responses to adoptively transferred T cells have been intermittently observed in patients with relapsed or resistant cancer, the overall response rate has been low. 6;7;9 For example, our previous experience using Epstein Barr Virus (EBV) specific cytotoxic T lymphocytes (CTL) for relapsed EBV-associated Hodgkin Disease (HD) generated CTL lines with low frequencies of cells specific for the weak EBV-derived antigens expressed by the tumor cells (e.g. LMP2) and produced responses only in a small proportion of patients, whose disease was limited. 10;11 Of the potential CTL target antigens expressed in EBV positive Hodgkin's Disease (HD) and non-Hodgkin's Lymphoma, EBNA-1-is not processed for presentation on class I
antigens by tumor cells 12 while wild type LMP1 is toxic when expressed in antigen presenting cells. 13 LMP2A, however, is consistently expressed on the malignant
For personal use only. on April 29, 2017 . by guest www.bloodjournal.org From populations in Lymphoma tumors (e.g. Hodgkin Reed-Sternberg cells) and its epitopes are conserved between viral strains and amongst lymphoma biopsy samples. 14;15 To bias the EBV-specific CTL response to LMP2, we have replaced LCLs as APCs for the first stimulation, with dendritic cells (DCs) engineered to express LMP2 from an adenovirus (Ad) vector and used LCLs overexpressing LMP2 from the same Ad vector for subsequent stimulations. 16;17 This approach expands polyclonal populations of both helper (CD4 + ) and cytotoxic (CD8 + ) T lymphocytes specific for this weak tumor antigen.
After infusion into patients diagnosed with LMP2-positive lymphomas, LMP2-reactive T cells increased in number in the circulation and at tumor sites and produced sustained tumor responses.
MATERIALS AND METHODS

Patients and LMP status of the tumors
The protocol for the use of LMP2-specific CTL as therapy for Lymphoma was approved by the Food and Drug Administration, the Recombinant DNA Advisory Committee and the Baylor College of Medicine Institutional Review Board and Institutional Biosafety
Committees. Informed consent was provided according to the Declaration of Helsinki.
Patients were eligible for this study if they had Epstein Barr Virus (EBV)-associated Type II latency Hodgkin's disease or Non-Hodgkin's lymphoma (NHL) detected by immunohistochemistry for LMP1 and/or in situ hybridization for EBER.
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Patients had either relapsed after receiving standard therapy ( Tables 1 and 2 . Complete blood counts were obtained, and electrolytes, renal and liver function were evaluated at 2, 4 and 6 weeks post-infusion and then at 3, 6, 9, and 12 months. Blood from patients was also monitored at regular intervals for EBV-DNA levels and immunologic assessment. Analysis of disease response to CTL therapy was performed using RECIST criteria.
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Generation of LMP-2 specific CTLs and EBV-specific CTLs 5 x 10 6 PBMC from each patient were used for the establishment of an EBV transformed B lymphoblastoid cell line (LCL) for use as APCs. 16 For DC production, PBMCs were plated overnight, then non adherent cells were cryopreserved and adherent cells were cultured with 800 U/ml GM-CSF (Sargramostim Leukine; Immunex, Seattle, WA) and 500 U/ml IL-4 (R&D Systems, Minneapolis, MN, USA) for 7 days. IL-4 and GM-CSF were again added on day 3. On day 5, immature DCs were harvested by vigorous pipetting, transduced with Ad5f35LMP2 vector, and treated with TNFα (R&D systems) and PGE1 (Merck) for maturation. Before co-culture with non-adherent PBMCs the DCs were gamma-irradiated (30Gy epitopes. EBV-specific CTL lines were produced as previously described. 24 . Briefly, PBMCs were cocultured with autologous irradiated (40Gy) LCls at a responder :
stimulator ration of 40:1 for 9 days and then restimulated weekly with the autologous LCL at a 4:1 ratio. The cultures were supplemented with 40 units per mL of IL-2 from day 13.
Cytotoxicity assays
The cytotoxic specificity of each CTL line was analyzed in a standard 4-hour chromium 51 release assay using effector:target ratios of 40:1, 20:1, 10:1, and 5:1. 25 The target cells tested were LMP2-positive: autologous LCL; HLA class I and II mismatched LCL; HLAmatched fibroblasts transduced with Ad5f35LMP2; or PHA blasts pulsed with the LMP2 pepmix (Jerini, Berlin, Germany). As additional controls, we used LMP2-negative target cells; autologous phytohemagglutinin-stimulated PBMC (PHA blasts) alone or pulsed with irrelevant peptides from a CMV pp65 pepmix,(Jerini), and HLA matched fibroblasts transduced with Ad5f35GFP.
Immunophenotyping
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Detection of EBV-DNA in PBMCs by Quantitative Real time PCR
DNA was isolated from 3 to 5×10 6 PBMCs using an anion exchange column (Qiagen, Valencia, CA). Five hundred nanograms of DNA was analyzed by EBV EBER-specific Q-PCR as previously described to quantitate EBV genome copy number per µg.
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LMP2-multimers and peptides
To detect LMP2-specific T cells in the CTL lines and PBMC, we used the soluble HLA- 
Statistical Analysis
Descriptive statistics were calculated to summarize SFC for LMP2-or EBV-specific T cells at pre-and post-infusion time points as well as the changes in SFC from preFor personal use only. on April 29, 2017 . by guest www.bloodjournal.org From infusion. Assessments of data normality on these outcomes were performed and data were log-transformed if indicated. Comparisons between pre-and post-infusion LMP2-specific and EBV (LCL)-specific T cells SFCs were performed using paired t-tests on log-transformed data. . Comparison of repeated measurements of LMP2 and EBV SFC levels over time between patients with vs. without LMP2 sensitivity in their CTL lines were performed using random coefficient models. P values < 0.05 were considered statistically significantly different.
RESULTS
Patient Characteristics
All patients had EBV positive lymphoma. 
CTLs are LMP2-specific and polyclonal
The specificity of the LMP2-CTL lines was determined using HLA-peptide multimers when available. Specific function was determined, using cytotoxicity assays and IFNγ ELISPOT assays. The cytolytic activity of the responder cells was tested against a panel of 51 Cr-labeled autologous and allogeneic target cells. Ten of the 16 lines infused had demonstrable LMP2-specific activity. LMP2-specific CTLs generated from a patient representative of these twelve patients killed autologous LCL and HLA-matched fibroblasts only if transduced with Ad5f35LMP2A (30% at an E: T ratio of 20:1 ( Figure   1a) ) whereas the LCL-activated EBV-specific CTL line demonstrated no LMP2 specific activity (data not shown). Killing was not due to adenovirus-directed CTLs, since fibroblasts infected with recombinant adenovirus encoding GFP were not recognized.
There was no cytotoxic activity against HLA-mismatched LCLs, (Figure 1a ) or untransduced fibroblasts (data not shown)
This same patient's HLA type was A2;29/B13;27. Using HLA A2, A29 and B27 multimers we demonstrated that CTL generated using Ad5f35LMP2-transduced APCs (LMP2-CTL)
were markedly enriched for T cells specific for LMP2 epitopes compared to the EBV-CTL line generated from the same patient using non-transduced LCL alone. Further, the Furthermore, using OKT3 blasts expressing LMP2 peptides as APCs we were able to demonstrate that both the CD4 + and CD8 + T cells present in the polyclonal CTL lines have LMP2 specificity (Figure 1d ). Hence the lines infused, though reactive to LMP2 are multispecific and are not restricted to predetermined peptide epitopes of LMP2, thereby reducing the probability of tumor immune-escape due to outgrowth of a single-epitope loss variant.
Adoptively-transferred LMP2-specific CTL lines expand in vivo
Sixteen patients received total numbers of CTL ranging from 4x10 7 /m 2 to 3.2x10 8 /m 2 .
Multimer and ELISPOT assays were performed to measure the frequency of LMP2-specific CTL in peripheral blood before and after infusion. During the follow-up period, 
Outcome
No short or long-term toxicities were observed after CTL infusion. Of the ten patients treated in remission of high-risk disease, 9 have remained in complete remission for up to 37 months post CTL ( Table 2 ). The tenth patient progressed within 8 weeks of receiving CTL.
Of the six patients with relapsed disease that was refractory to standard treatment ( LMP2 is an EBV encoded latency protein expressed in up to 40% of all lymphomas. 31 It is apparent that EBV-associated lymphomas arising in the immunocompetent host lack expression of viral proteins that dominate the human T cell response following exposure to the virus. [32] [33] [34] Most EBV positive lymphomas arising in the immunocompetent host are characterized as viral latency pattern II, and express the EBV antigens EBNA-1, LMP1
and LMP2. We chose LMP2 as the target antigen for the current trial since EBNA1 is processed and presented poorly to classical CD8+ T cells [35] [36] [37] and LMP1 shows significant sequence variability between viral strains. 38 By contrast, LMP2 is consistently expressed, and its epitopes are conserved.
39-41
To express whole LMP2 protein in APCs, we used an adenovirus vector, Ad5f35, encoding LMP2 as a transgene. This choice allows APCs and T cells to "self-select" the processed peptides they present and react with, so that generation of LMP2-specific T cells is not restricted to patients whose HLA-polymorphisms are appropriately matched to the individual peptides used. Although our study is not randomized, these lymphomas do not undergo spontaneous complete remission, so that the clinical responses we observed are likely causally related to the anti-tumor activity of the CTLs we infused. Of note, benefits were obtained in the absence of the severe morbidity and mortality that are an inevitable accompaniment to conventional salvage chemo-radiation.
Our technique using genetically modified APC that overexpress weak antigens may have utility for preparing effector cells that target other "weak" tumor associated
For personal use only. on April 29, 2017 . by guest www.bloodjournal.org From antigens, since it favors expansion of T cells present at low frequencies, and with low antigen affinity (Figure 1a) . This current study, however, modulates the response to a weak viral-derived tumor antigen and it is possible that it will be less effective for tumorantigens that are of host origin. Even if such a limitation applies, this approach should nonetheless prove valuable for the targeted treatment of other viral-associated malignancies of the head and neck, the cervix, and the hemopoietic system. Furthermore, the clinical outcome we report, taken in conjunction with successful studies in which the T lymphocytes themselves are genetically modified to express tumor specific receptors, 9 demonstrates that the convergence of cellular immunotherapy and gene transfer can be of clinical value.
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infiltrating T cells were seen in lymph node biopsy post-CTL infusion which corresponded to a clearance of LMP2+ tumor cells (Figure 3b) . In addition, the percent 
CD8
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